Are you an experienced Clinical Project Manager with a strong track record in international clinical drug development? Do you enjoy taking responsibility, solving problems and working with scientific experts to advance promising new treatments?
BioArctic is looking for an experienced Senior Clinical Project Manager to lead complex international clinical trials in different stages. Although the current opening focuses on phase II-III, additional opportunities focusing on early clinical development may also soon become available. Therefore, we welcome applications from candidates with relevant experience across different phases of clinical development.
The role
You will lead the operational planning, execution and oversight of international clinical trials, from start-up through close-out. Working closely with cross-functional teams, CROs and external experts, you will ensure studies progress according to agreed timelines, budgets, quality standards and regulatory requirements.
Your main responsibilities will include:
Leading complex clinical trials and coordinating cross-functional teams.
Managing CROs and vendors, including sponsor oversight, performance and change management.
Managing study risks, resources and financial oversight.
Ensuring regulatory compliance, quality and inspection readiness.
Contributing to study documentation, regulatory submissions and clinical development planning.
Representing BioArctic in discussions with investigators and external partners.
Your background
For this position, we are looking for someone with:
Extensive experience in international clinical project management, particularly leading large, complex Phase II and III trials.
Experience from both large pharmaceutical companies and smaller biotech or R&D organisations.
Extensive experience in sponsor oversight, CRO management and change management.
Strong cross-functional leadership, financial and resource management skills.
A strong business mindset, balancing scientific goals with priorities, resources and risks to drive successful drug development.
Experience with clinical trial documentation and regulatory submissions, including IND/CTA.
Thorough knowledge of ICH-GCP, EU Clinical Trials Regulation, risk management and inspection readiness.
A university degree in a relevant life science discipline.
Experience in CNS, rare diseases or biopharmaceuticals is an advantage.
The role is based in Stockholm, with on-site presence preferred. Flexibility may be discussed for the right candidate.
Future opportunities at BioArctic
BioArctic may also recruit a Senior Clinical Project Manager focusing on Phase I and first-in-human studies. We therefore welcome applications from equally experienced project managers specialising in early clinical development, even if the advertised Phase II–III position is not the right match.
As part of the application, you will be asked to indicate whether you are interested in the advertised position, future Phase I/first-in-human opportunities, or both.
Who you are
You are independent, proactive and structured, with sound judgement and a pragmatic, business-oriented approach. You communicate clearly, build strong relationships and can influence others without formal authority. You are comfortable making decisions, challenging CROs when necessary and maintaining focus under pressure.
More information and contact
For more information, please contact Anna Rennermalm at Search4S, +46 707 94 20 05, [email protected]
Apply via link. Applications will be reviewed on an ongoing basis. Last application date: Nov 29th 2026.
NB: When clicking "apply", you will be redirected to the ad at BioArctic's career site.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases.
The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally.
In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment.
BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. BioArctic’s head office is located in Stockholm Sweden, and the company has more than 150 employees.
For further information, please visit www.bioarctic.com.